Condition: Acute Myeloid Leukemia · Sponsor: Stemline Therapeutics, Inc.
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy.
This description comes directly from the study's public registry record.
Stemline Trials · 1-877-332-7961 · clinicaltrials@menarinistemline.com
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles | Los Angeles, California, United States | Recruiting |
| Stanford Health Care | Stanford, California, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| AdventHealth Cancer Institute | Orlando, Florida, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Dana Farber Cancer Institute (DFCI) | Boston, Massachusetts, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Health System Brigitte Harris Cancer Pavillion | Detroit, Michigan, United States | Recruiting |
| Washington University - Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
| John Theurer Cancer Center - Hackensack Meridian Health | Hackensack, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06456463